Related Research Articles
Mansukh C. Wani,, was a principal scientist (emeritus) at the Research Triangle Institute in North Carolina. He was co-discoverer of Taxol and camptothecin, two anti-cancer drugs considered standard in the treatment to fight ovarian, breast, lung and colon cancers. In 2000, Wani received an award for applied research in medicine, the Charles F. Kettering Prize, from the General Motors Cancer Research Foundation.
Carolyn Ruth Bertozzi is an American chemist and Nobel laureate, known for her wide-ranging work spanning both chemistry and biology. She coined the term "bioorthogonal chemistry" for chemical reactions compatible with living systems. Her recent efforts include synthesis of chemical tools to study cell surface sugars called glycans and how they affect diseases such as cancer, inflammation, and viral infections like COVID-19. At Stanford University, she holds the Anne T. and Robert M. Bass Professorship in the School of Humanities and Sciences. Bertozzi is also an Investigator at the Howard Hughes Medical Institute (HHMI) and is the former director of the Molecular Foundry, a nanoscience research center at Lawrence Berkeley National Laboratory.
Dale Lester Boger is an American medicinal and organic chemist and former chair of the Department of Chemistry at The Scripps Research Institute in La Jolla, CA.
Bruce Eliot Maryanoff FRSC is an American medicinal and organic chemist.
Richard Bruce Silverman is the Patrick G. Ryan/Aon Professor of Chemistry at Northwestern University. His group's main focus is basic and translational research into central nervous system disorders and cancer. He is known for the discovery of pregabalin, which is marketed by Pfizer under the brand name Lyrica.
Paul S. Anderson is an American chemist. He worked at Merck, DuPont-Merck, and Bristol-Myers Squibb.
Cynthia "Cyndie" Anne Maryanoff is an American organic and materials chemist. Among other awards, she received the 2015 Perkin Medal for outstanding work in applied chemistry in the U.S.A.
Robert Vince is an American scientist known for his contributions to the research in the area of drug design. He is currently the director and professor at the Center for Drug Design at the Academic Health Center for the University of Minnesota.
Ann E. Weber is the senior vice president for drug discovery at Kallyope Inc. in New York City. She previously worked with Merck Research Laboratories (MRL), joining the company in 1987 and retiring from the position of vice president for lead optimization chemistry in 2015. She has helped develop more than 40 drug candidates including FDA-approved treatments for Type 2 diabetes. She has received a number of awards, including the Perkin Medal (2017) and has been inducted into the ACS Division of Medicinal Chemistry’s MEDI Hall of Fame.
John Albert Katzenellenbogen is an American Professor of Chemistry at the University of Illinois at Urbana-Champaign. He studies the development of novel agents for the treatment of hormone-responsive and non-responsive breast and prostate cancers and the design of estrogens and antiestrogens that have a favorable balance of beneficial versus detrimental effects.
Gunda I. Georg is a chemist who is currently the Professor and Head of the Department of Medicinal Chemistry, Regents Professor, McKnight Presidential Chair, Robert Vince Endowed Chair at University of Minnesota and a former Co-Editor-in-Chief of American Chemical Society's Journal of Medicinal Chemistry. Her research interests are total synthesis and semisynthesis as well as evaluating biologically active agents. A cited expert in her field, she was elected to the American Association for the Advancement of Science in 1996 and inducted in the Medicinal Chemistry Hall of Fame in 2017. In 2019, she was announced as the 2020 winner and first woman to receive the Alfred Burger Award in Medicinal Chemistry. She along with chemists, Shameem Syeda and Gustavo Blanco, are leading researchers in male contraception. Dr Georg also works with her research groups to conduct research on Alzheimer's disease, epilepsy and cancer experimental therapeutics.
Donna M. Huryn is an American medicinal and organic chemist. She received her B.A. (chemistry) from Cornell University, and Ph.D. in organic chemistry from the University of Pennsylvania. She is on the faculty at the University of Pittsburgh’s school of pharmacy, holds an adjunct appointment in the department of chemistry at the University of Pennsylvania, is the principal investigator of the University of Pittsburgh Chemical Diversity Center, and was a visiting fellow in the summer of 2017 at the University of Bologna. She is a fellow of the American Chemical Society, recipient of the ACS Philadelphia Local Section Award, has held a number of elected positions within the American Chemical Society at both the local and national levels, and is 2015 Chair of the Division of Organic Chemistry. Huryn also formed, along with a number of other scientists, the Empowering Women in Organic Chemistry Conferences in 2019. The goal was to empower and bring the research and career of all marginalized individuals in chemistry-related fields to the forefront of the scientific community. Huryn noticed how there was not enough women pursuing and maintaining a career in organic chemistry, and thus founded this organization. The Empowering Women in Organic Chemistry Conferences allowed for women leaders to present their scientific findings and hear the stories of how eminent women in the field of organic chemistry overcame the challenges they faced being female. She is associate editor of ACS Medicinal Chemistry Letters. She in also an editor of the journal Organic Reactions and co-authored the textbook Medicinal Chemistry and the article "Medicinal Chemistry: Where Are All the Women?" which appeared in the ACS Medicinal Chemistry Letters Journal. Huryn’s research focuses on the design and synthesis of small molecules probes and drugs to treat cancer, neurodegenerative and infectious diseases.
Karin Briner is a medicinal chemist and pharmaceutical executive currently employed as the Vice President and Global Head of Chemistry at Novartis.
Wendy B. Young is a medicinal chemist and pharmaceutical executive currently employed at Genentech.
Alexandros Makriyannis is an American biochemist and professor of chemistry and chemical biology in the department of medicinal chemistry at Northeastern University in Boston, Massachusetts, where he directs the Center for Drug Discovery and holds the George Behrakis Chair of Pharmaceutical Biotechnology. His research has focused on the biochemical basis of the endocannabinoid system and on the development of synthetic cannabinoids.
Iwao Ojima is a Japanese-American chemist and university distinguished professor at the State University of New York at Stony Brook. He has been widely recognized for his seminal contributions to a range of chemical research at the multifaceted interfaces of chemical synthesis and life sciences. As rare accomplishments, he has received four National Awards from the American Chemical Society in four different fields of research. He is also serving as the director of the Institute of Chemical Biology and Drug Discovery (ICB&DD), as well as the president of the Stony Brook Chapter of the National Academy of Inventors.
Anabella P. Villalobos is a medicinal chemist and senior pharmaceutical executive at Biogen.
Peter Grootenhuis was a Dutch-American Medicinal Chemist. Grootenhuis was the Project Leader and Co-Inventor of Ivacaftor (VX-770), the first CFTR potentiator FDA approved drug to treat the underlying cause of Cystic Fibrosis (CF) in patients with certain mutations in the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene, who account for 4-5% of CF cases. Grootenhuis also led the Vertex team to subsequent discovery of Orkambi, the combination of Ivacaftor and Lumacaftor(VX-809), approved to treat CF in people with two copies of the F508del mutation. Most recently, Grootenhuis's team discovered Tezacaftor (VX-661) and Elexacaftor (VX-445), which in combination with Ivacaftor are the components of Trikafta, a drug approved by the FDA in 2019 to treat CF in more than 90% of CF patients. For Grootenhuis’ contributions to the discovery of these compounds, he was awarded the 2018 IUPAC Richter Prize, the American Chemical Society’s 2013 Heroes of Chemistry Award, and inducted into the American Chemical Society Division of Medicinal Chemistry Hall of Fame. Grootenhuis has contributed to the discovery of over 11 clinical candidates, co-authored more than 100 peer reviewed papers and is inventor of 65 + U.S Patents, and more than 50 EU Patents.
Amy Hauck Newman is an American medicinal chemist who is the scientific director of the intramural research program at the National Institute on Drug Abuse. She researches the design, synthesis, and evaluation of central nervous system (CNS) active agents as potential treatment medications for substance use disorders, with an emphasis on selective ligands for the dopaminergic system.
References
- 1 2 Jarvis, Lisa. "E. B. Hershberg Award For Important Discoveries In Medicinally Active Substances | Chemical & Engineering News". cen.acs.org. Retrieved 2018-11-21.
- 1 2 "Ruth R. Wexler, Ph.D." www.acsmedchem.org. Retrieved 2018-11-21.
- ↑ "Wexler, Ruth | Amos Smith Research Group". www.sas.upenn.edu. Retrieved 2018-11-21.
- ↑ Quan, Mimi L.; Pinto, Donald J. P.; Smallheer, Joanne M.; Ewing, William R.; Rossi, Karen A.; Luettgen, Joseph M.; Seiffert, Dietmar A.; Wexler, Ruth R. (2018-05-18). "Factor XIa Inhibitors as New Anticoagulants". Journal of Medicinal Chemistry. 61 (17): 7425–7447. doi:10.1021/acs.jmedchem.8b00173. ISSN 0022-2623. PMID 29775297.
- ↑ "MEDI Hall of Fame Inductees". www.acsmedchem.org. Retrieved 2018-11-21.